| Name | Title | Contact Details |
|---|
Engine Media Holdings Inc. operates as a holding company. The Company, through its subsidiaries, focuses on esports content, streaming technology, gaming platforms, data analytics, and intellectual property. Engine Media Holdings serves customers worldwide.
Blue Giant Equipment Corporation is a prominent global manufacturer and distributor of loading dock systems and material handling equipment, headquartered in Toronto, Ontario, Canada. Founded in 1963 by Kurt Larsen, the company has celebrated over 60 years of innovation in the industry. Blue Giant began with mechanical dock levelers and hand pallet trucks, later expanding its offerings to include intelligent dock controls and air-powered loading dock equipment. The company provides a wide range of products, including loading dock systems, material handling equipment, HVLS fans, and ergonomic lift assist solutions. Their innovative Blue Genius Connect control panel enhances the management of loading dock operations. Blue Giant has received multiple awards for its products, including recognition in the Professional Door Dealer magazines "Best of Business Dealers Choice Poll" and a Bronze Award from Plant Engineering magazine. With a commitment to growth, Blue Giant relocated its headquarters in 2017 to a larger facility in Mississauga, Ontario, reflecting its dedication to expanding its capabilities in the material handling sector.
Ingersoll Rand Inc. (NYSE:IR), driven by an entrepreneurial spirit and ownership mindset, is dedicated to Making Life Better for our employees, customers, shareholders, and planet. Customers lean on us for exceptional performance and durability in mission-critical flow creation and industrial solutions. Supported by over 80+ respected brands, our products and services excel in the most complex and harsh conditions. Our employees develop customers for life through their daily commitment to expertise, productivity, and efficiency. For more information, visit www.IRCO.com.
Manhattan School of Music (MSM) is a renowned private music conservatory located in New York City, founded in 1917-1918 by pianist and philanthropist Janet D. Schenck. Originally established as the Neighborhood Music School in East Harlem, MSM has built a strong reputation for excellence in music education, influenced by notable artists like Pablo Casals and Harold Bauer. The school offers a range of academic programs, including Bachelor of Music, Master of Music, and Doctor of Musical Arts degrees. MSM specializes in classical and jazz performance, composition, conducting, and music education, and features a prominent opera program. Its campus in Morningside Heights includes instructional spaces, performance venues, and a residence hall, with facilities like the Hubbard Recital Hall, which houses a distinguished Aeolian-Skinner organ. MSM attracts a diverse student body of aspiring professional musicians from around the world, providing rigorous training and numerous performance opportunities. The institution is dedicated to fostering professional musicianship in both classical and jazz traditions.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.